Martin Svaton1, Ondrej Fiala2, Milos Pesek3, Zbynek Bortlicek4, Marek Minarik5, Lucie Benesova5, Ondrej Topolcan6. 1. Department of Pneumology, University Hospital Pilsen, Charles University in Prague, Prague, Czech Republic svatonm@gmail.com. 2. Department of Oncology and Radiotherapy, University Hospital Pilsen, Charles University in Prague, Prague, Czech Republic Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic. 3. Department of Pneumology, University Hospital Pilsen, Charles University in Prague, Prague, Czech Republic. 4. Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic. 5. Centre for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic. 6. Department of Nuclear Medicine, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
Abstract
BACKGROUND/AIM: The prognostic and predictive value of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation in non-small cell lung cancer (NSCLC) is not well established. The present study aimed at the elucidation of the role of KRAS mutation in prediction of outcome of patients with advanced NSCLC receiving second- or third-line chemotherapy. PATIENTS AND METHODS: The outcome of 127 patients with advanced NSCLC who recieved pemetrexed or docetaxel at second- or third-line therapy was retrospectively analyzed. RESULTS: Progression-free survival was not significantly different between patients with KRAS mutation and those with wild-type KRAS. The results were the same even when taking into account the specific KRAS mutation. Overall survival was significantly longer for patients with wild-type KRAS vs. those with KRAS mutation (16.1 vs. 7.2 months, p=0,008). We observed shorter overall survival for those with G12C KRAS mutation vs. other KRAS mutations (median 10.3 vs. 6.4 months, p=0.011). CONCLUSION: The presence of KRAS mutation (especially KRAS G12C mutation) correlated with adverse prognosis in patients treated with second- or third-line pemetrexed or docetaxel. Copyright
BACKGROUND/AIM: The prognostic and predictive value of Kirsten ratsarcoma viral oncogene homolog (KRAS) mutation in non-small cell lung cancer (NSCLC) is not well established. The present study aimed at the elucidation of the role of KRAS mutation in prediction of outcome of patients with advanced NSCLC receiving second- or third-line chemotherapy. PATIENTS AND METHODS: The outcome of 127 patients with advanced NSCLC who recieved pemetrexed or docetaxel at second- or third-line therapy was retrospectively analyzed. RESULTS: Progression-free survival was not significantly different between patients with KRAS mutation and those with wild-type KRAS. The results were the same even when taking into account the specific KRAS mutation. Overall survival was significantly longer for patients with wild-type KRAS vs. those with KRAS mutation (16.1 vs. 7.2 months, p=0,008). We observed shorter overall survival for those with G12CKRAS mutation vs. other KRAS mutations (median 10.3 vs. 6.4 months, p=0.011). CONCLUSION: The presence of KRAS mutation (especially KRASG12C mutation) correlated with adverse prognosis in patients treated with second- or third-line pemetrexed or docetaxel. Copyright
Authors: Vincent L Cannataro; Stephen G Gaffney; Carly Stender; Zi-Ming Zhao; Mark Philips; Andrew E Greenstein; Jeffrey P Townsend Journal: Oncogene Date: 2018-02-16 Impact factor: 9.867
Authors: Helena Linardou; Vassiliki Kotoula; George Kouvatseas; Giannis Mountzios; Vasilios Karavasilis; Epaminondas Samantas; Anna Kalogera-Fountzila; Despina Televantou; Kyriaki Papadopoulou; Xanthipi Mavropoulou; Emily Daskalaki; Thomas Zaramboukas; Ioannis Efstratiou; Sofia Lampaki; Grigorios Rallis; Eleni Res; Konstantinos N Syrigos; Paris A Kosmidis; Dimitrios Pectasides; George Fountzilas Journal: Cancer Genomics Proteomics Date: 2019 Nov-Dec Impact factor: 4.069
Authors: Jacqueline V Aredo; Sukhmani K Padda; Christian A Kunder; Summer S Han; Joel W Neal; Joseph B Shrager; Heather A Wakelee Journal: Lung Cancer Date: 2019-05-15 Impact factor: 6.081